{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T09:32:05Z","timestamp":1789810325440,"version":"4.0.1"},"reference-count":28,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2000,6,1]],"date-time":"2000-06-01T00:00:00Z","timestamp":959817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2000,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Oropharyngeal and esophageal candidiasis (OPEC) is a frequent opportunistic mycosis in immunocompromised patients. Azole-resistant OPEC is a refractory form of this infection occurring particularly in human immunodeficiency virus (HIV)-infected patients. The procedures developed by the Antifungal Subcommittee of the National Committee for Clinical Laboratory Standards (NCCLS) are an important advance in standardization of in vitro antifungal susceptibility methodology. In order to further understand the relationship between NCCLS methodology and antifungal therapeutic response, we studied the potential correlation between in vitro susceptibility to fluconazole and in vivo response in a rabbit model of fluconazole-resistant OPEC. MICs of fluconazole were determined by NCCLS methods. Three fluconazole-susceptible (FS) (MIC, \u22640.125 \u03bcg\/ml) and three fluconazole-resistant (FR) (MIC, \u226564 \u03bcg\/ml) isolates of\n            <jats:italic>Candida albicans<\/jats:italic>\n            from prospectively monitored HIV-infected children with OPEC were studied. FR isolates were recovered from children with severe OPEC refractory to fluconazole, and FS isolates were recovered from those with mucosal candidiasis responsive to fluconazole. Fluconazole at 2 mg\/kg of body weight\/day was administered to infected animals for 7 days. The concentrations of fluconazole in plasma were maintained above the MICs for FS isolates throughout the dosing interval. Fluconazole concentrations in the esophagus were greater than or equal to those in plasma. Rabbits infected with FS isolates and treated with fluconazole had significant reductions in oral mucosal quantitative cultures (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.001) and tissue burden of\n            <jats:italic>C. albicans<\/jats:italic>\n            in tongue, soft palate, and esophagus (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.001). In comparison, rabbits infected with FR isolates were unresponsive to fluconazole and had no reduction in oral mucosal quantitative cultures or tissue burden of\n            <jats:italic>C. albicans<\/jats:italic>\n            versus untreated controls. We conclude that there is a strong correlation between in vitro fluconazole susceptibility by NCCLS methods and in vivo response to fluconazole therapy of OPEC due to\n            <jats:italic>C. albicans<\/jats:italic>\n            .\n          <\/jats:p>","DOI":"10.1128\/jcm.38.6.2369-2373.2000","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T19:47:27Z","timestamp":1583783247000},"page":"2369-2373","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":45,"title":["Correlation between In Vitro and In Vivo Antifungal Activities in Experimental Fluconazole-Resistant Oropharyngeal and Esophageal Candidiasis"],"prefix":"10.1128","volume":"38","author":[{"given":"Thomas J.","family":"Walsh","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute,1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina E.","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute,1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Piscitelli","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Pharmacy Department, National Institutes of Health Warren Grant Magnuson Clinical Center,2 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Bacher","sequence":"additional","affiliation":[{"name":"<!--label omitted: 3-->Veterinary Resources Program, Nation Center for Research Resources, National Institutes of Health,3Bethesda, Maryland 20892"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Peter","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute,1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Torres","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute,1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiva","family":"Shetti","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute,1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Katsov","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute,1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Kligys","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute,1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caron A.","family":"Lyman","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute,1"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/170.2.384"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.7.1530"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.5.1317"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/12.Supplement_3.S318"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.3.656"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.1997.12113186"},{"key":"e_1_3_1_8_2","doi-asserted-by":"crossref","unstructured":"Gibaldi\nM.\nPerrier\nD.\nPharmacokinetics\n2nd ed.\n1982\n445\n449\nMarcel Dekker Inc.\nNew York N.Y","DOI":"10.1201\/b14095"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001432-199712000-00007"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/35.1.103"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)81975-4"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/173.1.219"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.5.1277"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/38.4.671"},{"key":"e_1_3_1_15_2","unstructured":"National Academy of Sciences\nGuide for the care and use of laboratory animals.\n1996\nNational Academy Press\nWashington D.C."},{"key":"e_1_3_1_16_2","unstructured":"National Committee for Clinical Laboratory Standards\nReference method for broth dilution antifungal susceptibility testing of yeasts. NCCLS document M27A.\n1997\nNational Committee for Clinical Laboratory Standards\nVillanova Pa"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/02681219780001291"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.1.196"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/18.2.240"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/174.4.821"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/24.2.235"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.1.1"},{"key":"e_1_3_1_23_2","first-page":"437","article-title":"Histopathological and immunohistochemical changes in gut-associated lymphoid tissues following treatment of rabbits with dexamethasone","volume":"64","author":"Roy M. J.","year":"1992","unstructured":"Roy M. J. Walsh T. J. Histopathological and immunohistochemical changes in gut-associated lymphoid tissues following treatment of rabbits with dexamethasone.Lab. Investig.641992437443","journal-title":"Lab. Investig."},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.3.575"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(94)90300-X"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.6.1342"},{"key":"e_1_3_1_27_2","first-page":"467","article-title":"Chronic silastic central venous catheterization for induction, maintenance, and support of persistent granulocytopenia in rabbits","volume":"38","author":"Walsh T. J.","year":"1988","unstructured":"Walsh T. J. Bacher J. Pizzo P. A. Chronic silastic central venous catheterization for induction, maintenance, and support of persistent granulocytopenia in rabbits.Lab. Anim. Med.381988467471","journal-title":"Lab. Anim. Med."},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.4.467"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.25.5.931-932.1987"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.38.6.2369-2373.2000","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.38.6.2369-2373.2000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T00:41:35Z","timestamp":1646440895000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JCM.38.6.2369-2373.2000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,6]]},"references-count":28,"aliases":["10.1128\/.38.6.2369-2373.2000"],"journal-issue":{"issue":"6","published-print":{"date-parts":[[2000,6]]}},"alternative-id":["10.1128\/JCM.38.6.2369-2373.2000"],"URL":"https:\/\/doi.org\/10.1128\/jcm.38.6.2369-2373.2000","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,6]]},"assertion":[{"value":"1999-11-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-02-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-06-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}